-
1 Comment
Galmed Pharmaceuticals Ltd is currently in a long term downtrend where the price is trading 14.7% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Galmed Pharmaceuticals Ltd's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 24.0% to $-10M since the same quarter in the previous year.
Finally, its free cash flow fell by 92.9% to $-8M since the same quarter in the previous year.
Based on the above factors, Galmed Pharmaceuticals Ltd gets an overall score of 1/5.
| ISIN | IL0011313900 |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| CurrencyCode | USD |
| Market Cap | 4M |
|---|---|
| Target Price | 12 |
| Beta | 0.7 |
| PE Ratio | None |
| Dividend Yield | None |
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for GLMD using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
